FCN-159
- Generic Name
- FCN-159
An Exploratory Study to Evaluate the Efficacy and Safety of FCN-159 in Patients With Brain Arteriovenous Malformations
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 10
- Registration Number
- NCT06913725
- Locations
- 🇨🇳
the Department of Neurosurgery, China International Neuroscience Institute, Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China
Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2024-08-14
- Target Recruit Count
- 30
- Registration Number
- NCT06553365
To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT05997602
- Locations
- 🇨🇳
Beijing Children's Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Sun Yat-Sen Memorial Hpsipital,Sun Yat-Sen Unniversity, Guangzhou, Guangdong, China
🇨🇳Shenzhen Children's Hospital, Shenzhen, Guangdong, China
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
Phase 1
Active, not recruiting
- Conditions
- Neurofibromatosis 1Plexiform NeurofibromaNF1
- Interventions
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT04954001
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Principal Investigator Hans, Gainesville, Florida, United States
🇪🇸Hospital Universitario Vall d'Hebron, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath